About Integral membrane protein GPR137C
Integral membrane protein GPR137C (GPR137C) is a protein
from Homo sapiens identified by UniProt accession
Q8N3F9, 429 residues long.
MolForge cross-references it against 0 known binders and
13 disease associations.
Target properties
| Protein name | Integral membrane protein GPR137C |
| UniProt accession | Q8N3F9 |
| Gene | GPR137C |
| Organism | Homo sapiens |
| Length | 429 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (13)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.21
- urinary metabolite measurement · score 0.11
- serum metabolite measurement · score 0.05
- prostate carcinoma · score 0.04
- sitting height measurement · score 0.02
- Ataxia-telangiectasia · score 0.02
- small cell lung carcinoma · score 0.01
- uterine leiomyosarcoma · score 0.01
- neoplasm · score 0.00
- Friedreich ataxia · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N3F9-F1 | alphafold | PREDICTED | 66.57 | — |
Amino-acid sequence (429 residues)
MRVSVPGPAA AAAPAAGREP STPGGGSGGG GAVAAASGAA VPGSVQLALS VLHALLYAAL FAFAYLQLWR LLLYRERRLS YQSLCLFLCL LWAALRTTLF SAAFSLSGSL PLLRPPAHLH FFPHWLLYCF PSCLQFSTLC LLNLYLAEVI CKVRCATELD RHKILLHLGF IMASLLFLVV NLTCAMLVHG DVPENQLKWT VFVRALINDS LFILCAISLV CYICKITKMS SANVYLESKG MSLCQTVVVG SVVILLYSSR ACYNLVVVTI SQDTLESPFN YGWDNLSDKA HVEDISGEEY IVFGMVLFLW EHVPAWSVVL FFRAQRLNQN LAPAGMINSH SYSSRAYFFD NPRRYDSDDD LPRLGSSREG SLPNSQSLGW YGTMTGCGSS SYTVTPHLNG PMTDTAPLLF TCSNLDLNNH HSLYVTPQN
Explore Integral membrane protein GPR137C with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets